F/M Investments’s Bristol-Myers Squibb BMY Stock Holding History

F/M Investments’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Buy	+24,103	New	+$1.38M	0.07%	151

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

F/M Investments's BMY Position: Q2 2026 in Review

F/M Investments opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 24,103 shares worth $1.39M. The stake represents 0.07% of the portfolio and ranks #151 among its holdings.

2,511 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

F/M Investments held 24,103 shares of Bristol-Myers Squibb worth $1.39M as of Q2 2026.
Bristol-Myers Squibb was a new F/M Investments position in Q2 2026.
Bristol-Myers Squibb made up 0.07% of F/M Investments's portfolio in Q2 2026, its #151 holding.
2,511 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.